Article Per Year (5 Year)
p-Index From 2021 - 2026
2.63
P-Index
This Author published in this journals
All Journal Jurnal Kesehatan Andalas B-Dent, Jurnal Kedokteran Gigi Universitas Baiturrahmah Majalah Kedokteran Andalas Bioscientia Medicina : Journal of Biomedicine and Translational Research The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy Jurnal Penyakit Dalam Indonesia Sriwijaya Journal of Internal Medicine
Vesri Yoga
Gastroenterohepatology Subdivision, Department Of Internal Medicine, Faculty Of Medicine, Universitas Andalas, Padang, Indonesia
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 14 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 14 Documents
Search

 1   2 
Korelasi Kadar Serum VEGF-A dengan Rasio Albumin-Kreatinin Urin pada Pasien Penyakit Ginjal Diabetik Syaiful, Hannie Q; Priyono, Drajad; Harun, Harnavi; Murni, Arina W; Hanif, Akmal M; Faheri, Eifel; Arnelis, Arnelis; Yoga, Vesri
Jurnal Penyakit Dalam Indonesia Vol. 12, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Diabetic kidney disease (DKD) is a major microvascular complication of diabetes mellitus, characterized by persistent albuminuria and a progressive decline in glomerular filtration rate (GFR), making it a leading cause of chronic kidney disease (CKD) and end-stage renal disease. Vascular endothelial growth factor-A (VEGF-A) is implicated in the pathogenesis of DKD, being overexpressed in the kidneys and contributing to increased vascular permeability, inflammation, and fibrosis. Albuminuria, an early indicator of renal damage in DKD, is a strong predictor of CKD progression and cardiovascular events. The urine albumin-to-creatinine ratio (UACR) is the recommended test for detecting and monitoring albuminuria. This study aimed to investigate the correlation between serum VEGF-A levels and UACR in patients with DKD. Methods. This cross-sectional analytical observational study involving DKD patients at the Outpatient Clinic of Dr. M. Djamil General Hospital Padang from May to October 2024. Demographic and clinical data were collected. Blood samples were taken for serum VEGF-A measurement using ELISA, and morning spot urine samples were collected for UACR measurement using immunoturbidimetry. Correlation analysis was performed using the Spearman test. Ethical approval was obtained from the Health Research Ethics Committee of Dr. M. Djamil General Hospital Padang. Results. A total of 30 PGD patients were included in the study. The mean age was 61.9 years (SD 9.75), and 53.3% of the participants were male.The mean serum VEGF-A level in DKD patients was 131.34 (SD 83.9) pg/ml, and the mean UACR was 403.90 (SD 53.1) mg/g creatinine. There was a very strong positive correlation between serum VEGF-A levels and UACR (r = 0.993, p < 0.05). Conclusions. Serum VEGF-A levels are very strongly and positively correlated with UACR in DKD patients. Serum VEGF-A may serve as a potential marker for assessing DKD progression and risk of complications, as well as a potential therapeutic target.
Kadar Transthyretin Plasma pada Lanjut Usia Sarkopenia dan Non-Sarkopenia Fahrurozi, R. Ifan A.; Martini, Rose D; Mulyana, Roza; Murni, Arina W; Decroli, Eva; Miro, Saptino; Viotra, Deka; Yoga, Vesri
Jurnal Penyakit Dalam Indonesia Vol. 12, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Sarcopenia is a geriatric syndrome marked by an age-related decline in muscle mass, which is affected by protein intake. Transthyretin is a visceral protein used to evaluate nutritional status and acts as a positive regulator of muscle mass. This study aimed to assess the difference in plasma transthyretin levels between elderly groups with and without sarcopenia. Methods. This was an analytical observational study with a cross-sectional approach. Subjects were elderly patients who visited the Internal Medicine Polyclinic of Dr. M. Djamil Hospital Padang and met the inclusion and exclusion criteria from August to September 2024. Subjects were classified into sarcopenic and non-sarcopenic groups, followed by an examination of plasma transthyretin levels. Sarcopenia was diagnosed using bio-impedance analysis (BIA) measurement, handgrip strength with a Jamar hydraulic hand dynamometer, and physical performance with a walking speed test. Plasma transthyretin levels were measured using the enzyme-linked immunosorbent assay (ELISA) method. Comparative analysis was performed using the unpaired T-test using SPSS 29.0. Results. Among total of 46 subjects who participated in this study, the majority of elderly individuals with sarcopenia were predominantly female. The mean plasma transthyretin level in the sarcopenic elderly group was 10.9 (3.3) mg/dL, while in the non-sarcopenic elderly group was 20.3 (2.5) mg/dL. Comparative analysis demonstrated a significant difference in plasma transthyretin levels between sarcopenic and non-sarcopenic elderly individuals (p < 0.001). Plasma transthyretin levels in the sarcopenic elderly group were lower compared to the non-sarcopenic elderly group. Conclusion. There is a significant difference in plasma transthyretin levels between sarcopenic and non-sarcopenic elderly individuals.
The Role of Immunotherapy in Hepatocellular Carcinoma (HCC) Nurhayani Fatimah; Vesri Yoga; Arnelis -; Saptino Miro
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 27, No 1 (2026): VOLUME 27, NUMBER 1, April, 2026
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/271202670-79

Abstract

Hepatocellular carcinoma (HCC) is an aggressive primary liver malignancy with a historically poor prognosis and limited treatment options. It accounts for approximately 75–85% of all liver cancer cases worldwide, with an estimated global incidence of about 9.5 per 100,000 person-years. According to GLOBOCAN 2022, the liver cancer mortality-to-incidence ratio in Indonesia is 0.99, indicating that nearly all patients diagnosed with HCC die from the disease. Systemic therapy, primarily sorafenib, a targeted therapy approved since 2007, has long been the mainstay for advanced cases, but it offers limited clinical benefit. In recent years, immunotherapy, particularly immune checkpoint inhibitors (ICIs), has significantly altered the therapeutic approach to HCC. These agents function by inhibiting regulatory pathways such as PD-1/PD-L1 and CTLA-4, thereby enhancing immune-mediated tumor clearance. Clinical trials, such as IMbrave150, have shown that combining atezolizumab and bevacizumab leads to notable improvements in both overall and progression-free survival compared to sorafenib, resulting in its approval as a first-line treatment. Similarly, combinations like durvalumab with tremelimumab have shown encouraging efficacy. Nonetheless, therapeutic resistance remains a challenge, often driven by the immunosuppressive tumor microenvironment. Emerging strategies, such as next-generation checkpoint blockades, adoptive cell therapy, therapeutic cancer vaccines, and oncolytic virotherapy, are under investigation to improve response rates. This review discusses current progress in immunotherapy for HCC, addresses clinical limitations, and explores potential future directions to enhance treatment success.
Efficacy and Safety of Endoscopic Anti-Reflux Therapy versus Sham or Proton Pump Inhibitor Control in Gastro-oesophageal Reflux Disease: A Meta-Analysis of Randomised Controlled Trials Tiffano Taufan Firdaus; Vesri Yoga
Sriwijaya Journal of Internal Medicine Vol. 4 No. 2 (2026): Sriwijaya Journal of Internal Medicine
Publisher : Phlox Institute: Indonesian Medical Research Organization

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59345/sjim.v4i2.296

Abstract

Background: Gastro-oesophageal reflux disease (GERD) is among the most prevalent chronic disorders, and lifelong proton pump inhibitor (PPI) dependence is common. Endoscopic anti-reflux therapies are minimally invasive alternatives between medical and surgical management, but individual device trials are small and the randomised evidence has largely been synthesised device by device. Objective: To pool the randomised evidence across all endoscopic anti-reflux modalities against a common control and provide a single, class-level estimate of benefit in adults with GERD. Methods: Four databases were searched for randomised controlled trials comparing endoscopic anti-reflux therapy (radiofrequency, suturing/plication, injection/implant, transoral incisionless fundoplication) with a sham procedure and/or continued PPI in adults with GERD. Risk ratios (RR) for treatment success were pooled with a DerSimonian–Laird random-effects model; heterogeneity was quantified with I² and a prediction interval; bias was appraised with Cochrane RoB 2.0. Results: Twelve trials were eligible; seven were pooled (536 participants; follow-up 3–6 months). Endoscopic anti-reflux therapy approximately doubled treatment success versus sham or PPI control (pooled RR 1.89, 95% CI 1.51–2.37; p<0.001; I² 23.6%; prediction interval 1.17–3.05) — about 28 percentage points absolute, NNT ≈4. The effect persisted across subgroup, low-risk-of-bias, current-device and leave-one-out analyses; a secondary PPI reduction/cessation analysis confirmed benefit (RR 1.82, 95% CI 1.43–2.30; I² 0%). Serious adverse events were infrequent, concentrated among injection/implant devices. Conclusion: In adults with GERD, endoscopic anti-reflux therapy produced a clinically meaningful, robust improvement in short-to-intermediate-term treatment success versus sham or continued PPI, consistently across device classes; durability and device-specific safety require ongoing evaluation.
Co-Authors Abd. Rasyid Syamsuri Abdul Alim Rahimi Akmal M Hanif Alexander Kam Alexander Kam Andry Kurniawan Andry Kurniawan Andry Kurniawan Andry Kurniawan Arnelis Arnelis - Arnelis . Arnelis Arnelis Arnelis Arnelis Arnelis Arnelis Bestari Jaka Deka Viotra Dela Hangri Jalmas Dwitya Elvira, Dwitya Eva Decroli Faheri, Eifel Fahrurozi, R. Ifan A. Fahrurozi, R. Ifan Arief Fauzar Fauzar Fauzar, Fauzar Harun Harnavi Jalmas, Dela Hangri Jersivindo Ranazeri Kam, Alexander Laksono Trisnantoro Martini, Rose D Mendhel Yanti Murdani Abdullah Murni, Arina W Nasrul Zubir Nasrul Zubir Nasrul Zubir Nasrul Zubir Nasrul Zubir Nurhayani Fatimah Priyono, Drajad R. Ifan Arief Fahrurozi Rahimi, Abdul Alim Ranazeri, Jersivindo Roza Kurniati Roza Kurniati Roza Mulyana Saptino Miro Saptino Miro, Saptino Steven, Rios Syaiful, Hannie Q Tiffano Taufan Firdaus Wahyudi .